Efficacy Of Intravenous Epoprostenol For Pulmonary Arterial Hypertension In 2 Treatment Eras

被引：0
|
作者：
Delcroix, M. [1 ]
Wuyts, W. [1 ]
Vandevelde, E. [1 ]
Koen, J. [2 ]
De Clippel, M. [3 ]
Baptista, R. [3 ]
Vachiery, J. -L. [3 ]
机构：
[1] Univ Hosp Leuven, Leuven, Belgium
[2] GSK Phamaceut, Wavre, Belgium
[3] Erasme Univ Hosp, Brussels, Belgium
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2013年 / 187卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3284
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Epoprostenol Therapy for Pulmonary Arterial Hypertension
    Akagi, Satoshi
    Nakamura, Kazufumi
    Matsubara, Hiromi
    Ogawa, Aiko
    Sarashina, Toshihiro
    Ejiri, Kentaro
    Ito, Hiroshi
    ACTA MEDICA OKAYAMA, 2015, 69 (03) : 129 - 136
  • [22] Veletri® and Flolan® (Epoprostenol Sodium) in the Treatment of Pulmonary Arterial Hypertension
    Chin, K. M.
    Badesch, D. B.
    Robbins, I. M.
    Tapson, V. F.
    Palevsky, H.
    Kim, N. H.
    Kawut, S. M.
    Frost, A.
    Benton, W. W.
    Lemarie, J. C.
    Bodin, F.
    Rubin, L. J.
    McLaughlin, V. V.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2012, 31 (04): : S28 - S28
  • [23] Conversion From Intravenous Epoprostenol Products To Inhaled Treprostinil For Pulmonary Arterial Hypertension
    Alnuaimat, H.
    Reardon, N. T.
    Cash, J. H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [24] Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil
    Ivy, D. Dunbar
    Claussen, Lori
    Doran, Aimee
    AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (05): : 696 - 698
  • [25] Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution
    Yanaka, Kenichi
    Guillien, Alicia
    Soumagne, Thibaud
    Benet, Justin
    Piliero, Nicolas
    Picard, Francois
    Pison, Christophe
    Sitbon, Olivier
    Bouvaist, Helene
    Degano, Bruno
    EUROPEAN RESPIRATORY JOURNAL, 2020, 55 (06)
  • [26] The use of intravenous epoprostenol for the treatment of pulmonary hypertension associated with scleroderma.
    Klings, ES
    Simms, RW
    Hill, NS
    Korn, J
    Farber, HW
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (03) : A159 - A159
  • [27] Acute hemodynamic effects of intravenous adenosine in patients with associated pulmonary arterial hypertension: Comparison with intravenous epoprostenol
    Rossi, Rosario
    Coppi, Francesca
    Sgura, Fabio
    Monopoli, Daniel
    Boriani, Giuseppe
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2018, 49 : 147 - 151
  • [28] Treatment of pulmonary arterial hypertension associated with congenital heart disease with intravenous epoprostenol: Impact of therapy on timing of transplantation
    Butzel, DW
    McLaughlin, VV
    Rich, S
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (05) : 402A - 402A
  • [29] Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension
    Simonneau, Gerald
    Rubin, Lewis J.
    Galie, Nazzareno
    Barst, Robyn J.
    Fleming, Thomas R.
    Frost, Adaani
    Engel, Peter
    Kramer, Mordechai R.
    Serdarevic-Pehar, Marjana
    Layton, Gary R.
    Sitbon, Olivier
    Badesch, David B.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2014, 33 (07): : 689 - 697
  • [30] Multicenter experience with the rapid transition to intravenous treprostinil from epoprostenol in pulmonary arterial hypertension
    Shapiro, Shelley
    Waxman, Aaron
    Schilz, Robert
    Strootman, Deb
    Rollins, Kristan
    Feldman, B. Jeremy
    CHEST, 2007, 132 (04) : 635S - 635S
12345